EMPIRE GENOMICS

NTRK IN HUMAN CANCER:

A TIMELINE

1982
First NTRK1 fusion identified in a colon tumor biospy.

1998
First ETV6-NTRK3 fusion identified in infantile fibrosarcoma.

2002
After identification of ETV6-NTRK3 in secretory breast carcinoma, researchers find that this fusion can transform mammary epithelial cells and is capable of causing oncogenesis across all germ layers.

2010
NTRK2 fusion identified in pilocytic astrocytoma, the most common childhood brain tumor.

2015
Entrectinib granted FDA Orphan Drug designation for the treatment of NTRK fusion-positive non-small cell lung cancer, colorectal cancer, and neuroblastoma.

2017
Larotrectinib found to be an effective suppressor of NTRK-fusion positive solid tumors, regardless of tumor histology or patient age.

2017
FDA grants breakthrough designation to larotrectinib and entrectinib for the treatment of NTRK fusion-positive solid tumors.

2018
2nd generation TRK inhibitors enter clinical trials.

2019
FDA grants priority review to entrectinib for treatment of NTRK fusion-positive locally advanced or metastatic solid tumors, with an anticipated action date of August 2019.

To View Our NTRK FISH Probe Catalog

visit www.empiregenomics.com/NTRK or call our office at (716) 856-3873

For in vitro use only | CE marked in certain countries | RUO in US and other countries